Meyer H, Scherling D, Karl W
Arzneimittelforschung. 1983;33(11):1528-34.
(+/-)-Ethylmethyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate (nitrendipine, Bay e 5009) 1, a calcium antagonistic 1,4-dihydropyridine derivative, is currently under development as an antihypertensive. A pharmacokinetic study with 14C-nitrendipine in the rat revealed as major metabolites the pyridine 2, 3, 4, 5, 6 and 9 using glc-, tlc- and gc/ms-techniques. A potential metabolic pathway is discussed involving oxidation to the pyridine form, saponification of the ester groups and hydroxylation of the methyl groups as general biotransformation steps. 1,4-Dihydropyridines bearing appropriate functionalities were precursors in the synthesis of the reference metabolites 2, 3, 4, 7, 8 and 10.
(±)-乙基甲基-1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3,5-吡啶二羧酸酯(尼群地平,Bay e 5009)1,一种钙拮抗1,4-二氢吡啶衍生物,目前正作为抗高血压药物进行研发。用14C-尼群地平在大鼠身上进行的药代动力学研究表明,使用气相色谱、薄层色谱和气相色谱/质谱技术,吡啶2、3、4、5、6和9是主要代谢产物。讨论了一种潜在的代谢途径,包括氧化为吡啶形式、酯基皂化和甲基羟基化作为一般生物转化步骤。带有适当官能团的1,4-二氢吡啶是参考代谢产物2、3、4、7、8和10合成中的前体。